Immune Thrombocytopenia Following Booster Dose of the Moderna mRNA-1273 Vaccine

Vaccine-mediated immune thrombocytopenia, although previously reported, is considered exceedingly rare. The probability of the incidence of profound thrombocytopenia following the COVID-19 mRNA-based vaccine has been less elucidated. We present the case of an 81-year-old female patient who became pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Breetz, Katherine A, Cooper, Daniel P, Reeves, Shane A, Lodhi, Samra Haroon, Ahmed, Taha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Emergency Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870602/
https://www.ncbi.nlm.nih.gov/pubmed/36699793
http://dx.doi.org/10.7759/cureus.32873
Descripción
Sumario:Vaccine-mediated immune thrombocytopenia, although previously reported, is considered exceedingly rare. The probability of the incidence of profound thrombocytopenia following the COVID-19 mRNA-based vaccine has been less elucidated. We present the case of an 81-year-old female patient who became profoundly thrombocytopenic with bleeding manifestations six days after the Moderna mRNA-1273 vaccine administration. Fortunately, she exhibited platelet count recovery after treatment with intravenous immunoglobulins and steroid therapy. Furthermore, we show that the inherent risk of COVID-19 infection leading to thrombocytopenia significantly outweighs the vaccine’s risk.

Ejemplares similares